Emergent BioSolutions receives $50M contract option from BARDA

Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent’s existing contract for the acquisition of CYFENDUS. Deliveries are expected to begin this calendar year and be complete by April 2025. This award follows a previously announced contract modification of $30.0 million to supply CYFENDUS this year. CYFENDUS vaccine was approved by the U.S. Food & Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age. Anthrax is a Tier 1 biological select agent due to its potential to be used for a bioterrorist incident and threat to public health and national security.